This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Rituxan
  • /
  • Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHO...
Clinical trial

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Read time: 2 mins
Last updated:1st Sep 2002
Source: Clinical Trials
Identifier: NCT00147121

To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma.

Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell lymphoma, Phase 2/3 study was planned. Comparison(s): An intensified bi-weekly version by shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.

Category Value
Date last updated at source 2016-12-20
Study type(s) Interventional
Expected enrolment 300
Study start date 2002-09-01
Estimated primary completion date 2010-02-01

View full details